At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
In Brief
A Phase 2 clinical trial evaluating doxorubicin + cyclophosphamide, paclitaxel + pazopanib, and 2 other interventions for Neoplasms, Breast. Completed, enrolled 101 participants across 143 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.
Study Details
Timeline
Interventions
4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
4 cycles of paclitaxel + pazopanib
neoadjuvant surgery for breast cancer
6 months of treatment with pazopanib monotherapy